echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Nice UK recommends TRK inhibitor VITRAKVI (larotrectinib) for NTRK gene fusion-positive solid tumors

    Nice UK recommends TRK inhibitor VITRAKVI (larotrectinib) for NTRK gene fusion-positive solid tumors

    • Last Update: 2020-05-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Bayer announced that its promyocyopin receptor kinase (TRK) inhibitor VITRAKVI (larotrectinib) was recommended by the National Institute for Health and Clinical Optimization (NICE) to treat neurotrophic tyrosine receptor kinase therapy (NTRK) gene fusion-positive locallate, metastatic or surgical lying that may cause serious health problems, and there are no other satisfactory treatment options for adults and pediatric patients with solid tumorsLarotrectinib is an oral TRK inhibitor that can be used to treat solid tumors with NTRK gene fusion, regardless of the source of the primary tumorNICE's decision is based on Phase I clinical trials in adult patients, Phase II NAVIGATE trials in adult and adolescent patients, and I/II childhood SCOUT trialsThe results of Larotrectinib showed a aggregate total clinical response rate (ORR) of 67% in adult and pediatric patients with NTRK gene fusion-positive solid tumorsIn people who did not include primary central nervous system tumors, THE ORR was 72%Amanda Cunnington,Bayer UK, said: 'Bayer is proud to work with NICE and NHS England throughout the assessment process to provide a new oral treatment for cancer patients integrated by NTRK'
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.